In Brief: St. Jude
This article was originally published in The Gray Sheet
Executive Summary
St. Jude: Begins U.S. marketing of the first three products in its Trilogy line of pacemakers, the DR (dual-chamber, rate-responsive), SR (single-chamber, rate-responsive), and DC (dual-chamber) following FDA approval of PMA supplements for the devices. The DR and DC pacemakers list for approximately $7,000, Pacesetter says, while the SR sells for slightly less. Pacesetter's DR+ and SR+, the "premier" products of the Trilogy line, are in U.S. clinicals under an investigational device exemption received from FDA in December 1994 ("The Gray Sheet" Jan. 2, In Brief)...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.